Join us on February 16 for a Virtual Town Hall. We will discuss the campaign, as well as the different ways that your involvement will help secure the future of our industry.
Last week we surveyed compounders about their knowledge of new laws, regs, and practice protocols. The results are in, and we’re seeing some holes in your expertise.
If you’re a pharmacy or facility owner who’s always looking for business-growing ideas and techniques to improve your operations, then APC’s 2023 Owner Summit, March 26-28, is for you.
Last Friday, FDA issued guidance on compounding certain ibuprofen oral suspension products...
Semaglutide seems to be everywhere. News stories in The Wall Street Journal. Vanity Fair. The New York Times.
With release of the revised USP <797>, the compounding gods have spoken. But like Job in the Bible, we’ve got questions.
We welcome and congratulate these 2023 leaders of APC’s standing committees...
Are you up-to-speed on recent regulatory and practice protocol changes? Take a moment to assess yourself—and to see how you measure up with your peers…
APHA, NCPA, and APC sent a joint letter to FDA this week, urging the agency to take action on suspension shortages.
The report that accompanies the FDA appropriation bill recently signed by President Biden includes several compounding directives for the agency.
FOLLOW US
